Lenvatinib (Lenvima, Kisplyx)

Lenvatinib at a glance

Lenvatinib is a targeted cancer medicine taken once daily as capsules. Verified brands include Lenvima and Kisplyx. It blocks several signals involved in cancer growth and the development of blood vessels that supply a tumour. Your oncologist decides whether it is suitable for your particular situation.

You may receive lenvatinib alone or with another medicine, such as pembrolizumab, everolimus or belzutifan. Each combination has its own dose, monitoring and precautions. Another person's capsule count or treatment schedule may be quite different from yours.

Blood-pressure checks, urine tests and blood tests are important throughout treatment. Side effects can often be managed with supportive care, a treatment pause or a lower dose. Contact the team early rather than waiting until symptoms stop you eating, drinking or managing daily life.

How lenvatinib works

Lenvatinib is a tyrosine kinase inhibitor, or TKI. It blocks growth-related proteins including vascular endothelial growth factor receptors, called VEGFRs, and fibroblast growth factor receptors, called FGFRs. It also affects other signalling proteins, including RET, KIT and PDGFR-alpha. These effects can interfere with tumour growth and blood supply.

Normal blood vessels and tissues use some of the same pathways. That helps explain why blood pressure, kidney filtering, bleeding and wound healing need attention. Targeted treatment is not free of effects on healthy tissues.

This medicine is different from checkpoint immunotherapy, although pembrolizumab may be part of the same regimen. It also differs from other medicines directed mainly at a specific RET or FGFR alteration. Finding a protein name in this explanation is not enough to decide which medicine is appropriate.

How the team decides whether it is suitable

The team considers your diagnosis, previous treatments, scans, symptoms, relevant molecular tests, organ function and treatment goals. Some combinations require particular tumour tests; lenvatinib is not universally selected by finding one VEGFR mutation. Ask which findings support your own plan.

Tell the team about high blood pressure, heart failure, an irregular heartbeat, stroke, heart attack, bleeding, aneurysms, kidney or liver disease, bowel problems and previous medicine allergies. A recent clot in an artery needs particular attention. Mention prior radiotherapy, operations, wounds and any fistula—an abnormal connection between organs or between an organ and the skin. European guidance advises against starting treatment when a fistula is present.

Kidney and liver impairment may require a different starting dose. Recommendations depend on the condition being treated; severe impairment cannot be managed with one standard reduction for everyone. Safety and effectiveness in children are not established, and European information advises against use below two years because of animal-study safety concerns.

Before treatment starts

High blood pressure should be controlled before the first dose. Your team checks blood pressure, urine protein, kidney and liver function, blood counts and blood salts such as calcium, potassium and magnesium. Thyroid tests and a pregnancy test, when relevant, are also arranged.

Discuss previous heart problems and medicines that affect heart rhythm. The current US information advises considering a baseline scan of heart-pumping function. An ECG records the heart's electrical activity; European information recommends ECG monitoring for all patients, with particular attention to those at increased risk. The team decides the tests and timing you need.

An oral examination and preventive dental care can help identify problems before treatment. Tell the team if you take denosumab or a bisphosphonate, medicines used for bone health, because these can add to the risk of jaw complications. Mention any planned extraction or dental surgery.

Before going home, have a written capsule schedule, a plan for diarrhoea and high blood-pressure readings, and a 24-hour contact number. If you cannot swallow capsules, ask the pharmacist to demonstrate the approved liquid-preparation method for your product.

How to take lenvatinib

Daily dose and capsule strengths

Take lenvatinib once daily at approximately the same time, with or without food. Capsules contain 4 mg or 10 mg. Your dose may require a combination of strengths. Check the milligram dose and capsule count whenever treatment is changed.

Starting doses vary considerably. For example, some regimens use 24 mg daily, some combinations use 20 mg or 18 mg, and certain weight-based regimens use 8 mg or 12 mg. These examples are not a menu from which to choose. Follow the exact prescription and do not substitute another person's dose or change it when your weight changes without advice.

Most schedules are continuous, but the oncologist may pause, reduce or stop treatment for side effects. A partner medicine has its own instructions. Do not assume that a change to lenvatinib automatically changes every medicine in the regimen.

Swallowing or preparing a suspension

Swallow capsules whole with water. Do not chew, crush or open them. The prescribing information also provides a method for dispersing intact capsules in liquid when needed; this is different from opening capsules and tipping out the powder. A pharmacist should teach the method and supply suitable measuring equipment.

US Lenvima permits water or apple juice for an oral suspension. European Lenvima and Kisplyx also permit milk. Use water only for a feeding-tube suspension. The pharmacist must confirm tube compatibility and the complete administration plan.

The authorised method uses up to five intact capsules in a small container or a 20 mL oral syringe, initially with 3 mL liquid. Allow ten minutes for the shells to disintegrate, then stir or shake for three minutes until fully disintegrated. Give the entire mixture. Rinse with an additional 2 mL liquid, give that rinse and repeat as instructed until no visible residue remains. The US method requires at least one further rinse; European instructions require at least two further rinses. Follow your own product's illustrated instructions, not an improvised recipe.

US instructions say to prepare three capsules at a time if a prescribed dose requires six. Ask the pharmacist to confirm how to divide preparation safely. Never use a kitchen teaspoon to measure these small volumes.

If a prepared suspension cannot be used immediately, the labels permit a covered container in a refrigerator at 2–8°C (35.6–46.4°F) for no more than 24 hours; discard it after that limit. European instructions say to shake for about thirty seconds after removing it from the refrigerator. Do not assume this refrigeration instruction applies to intact capsules.

Missed dose, vomiting and storage

If you miss a dose, follow your pack's twelve-hour rule. The US patient information says to skip the missed dose if the next dose is due within twelve hours; otherwise take it when remembered. Professional information uses whether the missed dose can be taken within twelve hours of its usual time. Ask the pharmacist to clarify an exact boundary if needed. Never double up.

If you vomit after taking lenvatinib, do not take a replacement dose. Take the next dose at the usual time. Contact the team if vomiting continues or you cannot keep fluids down. An accidental extra dose needs prompt medical advice.

Keep intact capsules in their original packaging, away from children, heat and moisture. European packs specify no higher than 25°C (77°F); US storage allows 20–25°C (68–77°F) with limited excursions. Return unwanted medicine through the pharmacy's recommended disposal route.

Monitoring and checking response

Blood pressure can rise early, often before you feel any different. US and European guidance recommends checking after one week, every two weeks during the first two months and at least monthly thereafter. Extra home measurements may be useful. Ask for a written threshold for calling the team and do not adjust blood-pressure tablets yourself.

Liver tests are checked before treatment, every two weeks for two months and at least monthly afterwards. Urine protein and kidney function are monitored regularly. An abnormal urine screening test may lead to a more detailed protein measurement. Blood salts are also followed; calcium is checked at least monthly.

Thyroid function is checked before and during treatment. US guidance specifies at least monthly testing. If you already take thyroid replacement, the dose may need adjustment to your individual thyroid-hormone target. Do not change it yourself.

Heart symptoms, ECG findings, weight, hydration and symptoms from the accompanying medicines are reviewed. Belzutifan combinations require additional attention to anaemia, oxygen levels and heart function. Pembrolizumab and everolimus introduce other specific risks, so read their information alongside this guide.

Scans, examination, symptoms and other disease-specific tests show whether treatment is helping. High blood pressure or another side effect does not prove that lenvatinib is working, and few side effects do not mean it is ineffective.

Common side effects and practical care

Diarrhoea, nausea and reduced appetite

Take prescribed anti-sickness or anti-diarrhoea medicines according to your written plan. Report diarrhoea early, especially if it is frequent, persists despite treatment or is accompanied by pain, blood or fever. Dehydration can worsen kidney problems. Drink regularly within any fluid limit you have been given and ask about oral rehydration if needed.

With pembrolizumab, diarrhoea may also reflect immune-related bowel inflammation, which needs a different assessment. Do not assume that every loose stool is simply an expected capsule effect.

Smaller meals, snacks and dietitian support may help when appetite or taste changes make eating difficult. Track unplanned weight loss. Persistent vomiting, dizziness or reduced urine needs prompt advice rather than further home treatment alone.

Hand-foot skin reaction and mouth soreness

Hands and feet may become tender, red, dry or peeling. Use a recommended moisturiser and comfortable shoes, and reduce rubbing, pressure and prolonged exposure to hot water. Report pain that affects walking, gripping or everyday tasks; treatment adjustment may be needed.

Gentle brushing and prescribed mouth care can help with a sore or dry mouth. Avoid foods that sting and report ulcers or difficulty eating. Everolimus combinations may need additional preventive mouth care from the start; use only the rinse prescribed for your regimen.

Fatigue, aches, voice and thyroid changes

Plan activity around your energy and balance rest with gentle movement. Discuss troublesome muscle or joint pain before starting new painkillers. Hoarseness or a change in voice can occur; persistent or worsening symptoms need review, particularly if swallowing or breathing is affected.

An underactive thyroid may contribute to tiredness, feeling cold or constipation. Blood tests help distinguish this from other causes. Hair thinning, rash and swelling can also occur. Side-effect patterns differ between single-medicine and combination regimens, so general percentages cannot predict your individual experience.

Important side effects to recognise

Blood pressure, heart and blood vessels

Very high blood pressure can cause severe headache, visual change, confusion, chest pain or breathlessness. These symptoms require urgent assessment. Do not wait for a home reading if seriously unwell. Heart-pumping problems can cause increasing breathlessness, ankle swelling, rapid weight gain or difficulty lying flat.

The September 2026 US information gives particular attention to heart dysfunction with lenvatinib, including with belzutifan. It advises considering a baseline heart scan and repeating assessment if heart-failure symptoms appear. Treatment may be held, reduced or permanently stopped depending on severity.

Clots in an artery can cause a heart attack or stroke. Sudden one-sided weakness, facial drooping, difficulty speaking or persistent chest pain is an emergency. Treatment is discontinued after an arterial clotting event. European information also warns about aneurysms and artery dissection, a tear in an artery wall; sudden severe chest, back or abdominal pain needs emergency help.

Bleeding, perforation and fistula

Report unexplained bruising, nosebleeds or blood in urine promptly. Coughing or vomiting blood, black tar-like stools, major bleeding or collapse needs emergency care. The team assesses extra bleeding risk when a tumour lies close to or involves a major blood vessel.

A hole in the stomach or bowel wall, called perforation, and abnormal connections called fistulas can occur. Severe abdominal pain, fever, swelling of the abdomen, coughing or choking when swallowing, or unusual leakage from an opening needs urgent assessment. A sudden painful chest with breathlessness can also indicate a collapsed lung. Do not assume these symptoms are ordinary indigestion or treatment-related diarrhoea.

Kidney, liver and blood-chemistry problems

Protein leaking into urine may initially cause no symptoms. More severe kidney problems can cause swelling, frothy urine or much less urine than usual. Significant protein loss may require a pause; nephrotic syndrome, a serious protein-loss condition, requires discontinuation.

Liver injury can cause yellow eyes or skin, dark urine, unusual abdominal pain or marked loss of appetite. People with underlying liver disease also need monitoring for confusion or unusual sleepiness that can accompany worsening liver function. These symptoms need prompt assessment.

Low calcium or other salt changes may cause tingling, cramps, palpitations or seizures. Do not treat these symptoms with supplements without blood tests and advice. Rarely, rapid breakdown of cancer cells causes tumour lysis syndrome, affecting blood chemistry and organs. People at increased risk need preventive measures and closer monitoring.

Heart rhythm and brain symptoms

Lenvatinib can prolong a heart-rhythm measurement called the QT interval. Low blood salts or other medicines can increase the risk. Fainting or a fast, irregular heartbeat needs urgent assessment.

A rare brain condition called posterior reversible encephalopathy syndrome, or PRES, can cause severe headache, seizures, confusion or visual loss. It is also called RPLS. Despite the word reversible, it is an emergency needing hospital assessment, often including an MRI scan and treatment interruption.

Wound healing and jaw health

Lenvatinib can slow wound healing. US guidance says to hold it for at least one week before elective surgery, and for at least two weeks after major surgery and until the wound has healed adequately. European information leaves interruption and restart timing to clinical judgement. Your surgeon and oncologist must agree the dates.

Jawbone damage, called osteonecrosis, has been reported. Report persistent jaw pain, swelling, loose teeth or a mouth wound that will not heal. US guidance advises a hold of at least one week before planned dental surgery or an invasive dental procedure when possible. This must be coordinated with the treating team, not arranged by stopping tablets yourself.

Other medicines and vaccinations

Give the pharmacist a complete list of medicines, supplements and herbal remedies. Medicines that prolong the QT interval should generally be avoided with lenvatinib under US guidance; a specialist must review any necessary combination. Some antibiotics, anti-sickness medicines and heart-rhythm medicines can be relevant. Separating doses by a few hours does not reliably remove this risk.

Blood thinners, medicines affecting blood pressure or kidney function, and bone-protecting medicines also need review. Do not add ibuprofen, aspirin, concentrated supplements or herbal products without checking. The accompanying cancer medicine may have substantial additional interactions; a rule for lenvatinib alone is not enough to clear the complete regimen.

Do not assume that all targeted medicines have the same grapefruit or acid-suppressant restriction. Ask the pharmacist for the specific food and medicine advice for your entire prescription.

Vaccines should be coordinated with the team. Non-live vaccines may be suitable, while live vaccines and timing after treatment require individual advice based on immunity and other treatments. There is no single post-treatment interval appropriate to every lenvatinib regimen.

Everyday life during treatment

Use a daily reminder and record doses, blood-pressure readings and significant symptoms. Keep the capsule pack or dose chart available when talking to the team so changes can be checked accurately.

Choose comfortable footwear and skin care that reduce friction on hands and feet. Ask for help if mouth soreness, taste change or fatigue affects meals and household tasks. Gentle activity can be useful, but avoid driving when dizzy, unusually tired or affected by vision problems.

Plan travel around blood tests and access to care. Protect medicines from excessive heat, and carry your prescription and emergency contact details. Tell other clinicians and your dentist about treatment before any procedure. There is no need to manage difficult side effects silently to demonstrate that you can tolerate treatment.

Fertility, pregnancy and breastfeeding

Lenvatinib can harm a developing baby. US guidance requires patients who could become pregnant to use effective contraception during treatment and for thirty days after the last dose. European guidance specifies highly effective contraception during treatment and for at least one month afterwards, with an added barrier method if using oral hormonal contraception because its effectiveness is uncertain.

The lenvatinib labels do not specify a fixed male contraception interval. Ask about fertility preservation and a contraception plan for both partners, particularly when other cancer medicines are included. Animal studies suggest possible effects on fertility; effects in humans are uncertain.

Do not breastfeed during treatment. US lenvatinib information requires waiting one week after the final dose; European information prohibits breastfeeding during treatment without giving that same fixed post-treatment interval. Partner medicines may require much longer contraception or breastfeeding precautions. The current US label explicitly says to follow the longest applicable period for the combination.

Contact the team promptly if pregnancy occurs or is suspected. Do not choose the shortest interval from different leaflets or make treatment changes without advice.

After a pause or the end of treatment

Continue monitoring until side effects and abnormal results are appropriately managed. Blood-pressure medicines may need adjustment after lenvatinib stops, but changes should follow the team's advice and readings. Persisting diarrhoea, swelling, bleeding, neurological symptoms or poor wound healing still needs assessment.

Restarting after surgery, a severe adverse effect or organ injury requires explicit instructions. Some problems require permanent discontinuation; feeling better alone does not establish that restarting is safe.

Maintain the contraception and breastfeeding plan for the full regimen and return unused capsules safely. Ask who will arrange scans, blood tests and ongoing support, and when to contact the team between follow-up appointments.

Frequently asked questions